MA50439A - Nouveaux dérivés de pyrazolo-pyrrolo-pyrimidine-dione utilisés en tant qu'inhibiteurs de p2x3 - Google Patents

Nouveaux dérivés de pyrazolo-pyrrolo-pyrimidine-dione utilisés en tant qu'inhibiteurs de p2x3

Info

Publication number
MA50439A
MA50439A MA050439A MA50439A MA50439A MA 50439 A MA50439 A MA 50439A MA 050439 A MA050439 A MA 050439A MA 50439 A MA50439 A MA 50439A MA 50439 A MA50439 A MA 50439A
Authority
MA
Morocco
Prior art keywords
pyrrolo
pyrimidine
inhibitors
derivatives used
dione derivatives
Prior art date
Application number
MA050439A
Other languages
English (en)
Inventor
Nico Bräuer
James Lindsay Carr
Ursinyova Nina Connelly
Adam James Davenport
Oliver Martin Fischer
Marcus Koppitz
Jens Nagel
Roland Neuhaus
Shelley Anne Parrott
Elisabeth Pook
Andrea Rotgeri
Holger Siebeneicher
Robert James Townsend
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of MA50439A publication Critical patent/MA50439A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA050439A 2017-10-27 2018-10-18 Nouveaux dérivés de pyrazolo-pyrrolo-pyrimidine-dione utilisés en tant qu'inhibiteurs de p2x3 MA50439A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17198769 2017-10-27

Publications (1)

Publication Number Publication Date
MA50439A true MA50439A (fr) 2021-05-19

Family

ID=60190695

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050439A MA50439A (fr) 2017-10-27 2018-10-18 Nouveaux dérivés de pyrazolo-pyrrolo-pyrimidine-dione utilisés en tant qu'inhibiteurs de p2x3

Country Status (26)

Country Link
US (1) US11319324B2 (fr)
EP (1) EP3700907B1 (fr)
JP (1) JP7250011B2 (fr)
KR (1) KR20200078567A (fr)
CN (1) CN111527090B (fr)
AU (1) AU2018354777A1 (fr)
BR (1) BR112020008122B1 (fr)
CA (1) CA3080249A1 (fr)
CL (1) CL2020001107A1 (fr)
CO (1) CO2020005065A2 (fr)
CR (1) CR20200174A (fr)
CU (1) CU20200038A7 (fr)
DK (1) DK3700907T3 (fr)
DO (1) DOP2020000100A (fr)
EA (1) EA202091003A1 (fr)
EC (1) ECSP20023626A (fr)
ES (1) ES2914377T3 (fr)
IL (1) IL274036A (fr)
JO (1) JOP20200100A1 (fr)
MA (1) MA50439A (fr)
MX (1) MX2020004981A (fr)
NI (1) NI202000031A (fr)
PE (1) PE20200932A1 (fr)
PH (1) PH12020550494A1 (fr)
SG (1) SG11202003662XA (fr)
WO (1) WO2019081343A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112778311B (zh) * 2019-11-01 2024-06-04 上海翰森生物医药科技有限公司 含氮并环类衍生物抑制剂、其制备方法和应用
TWI886184B (zh) * 2019-12-10 2025-06-11 大陸商上海翰森生物醫藥科技有限公司 含吡唑多環類衍生物抑制劑、其製備方法和應用
WO2022175514A1 (fr) * 2021-02-22 2022-08-25 Bayer Aktiengesellschaft N-(pyridin-2-yl)-acétamides utilisés comme inhibiteurs de p2x3
BR112023025543A2 (pt) * 2021-06-09 2024-02-27 Jiangsu Hansoh Pharmaceutical Group Co Ltd Forma de sal e cristal de derivado policíclico contendo pirazol, e método de preparação do mesmo e uso do mesmo
WO2023021328A1 (fr) * 2021-08-17 2023-02-23 Bellus Health Cough Inc. Préparation d'un antagoniste de p2x3
AR132698A1 (es) * 2023-05-17 2025-07-23 Insilico Medicine Ip Ltd DERIVADOS ESPIRO COMO INHIBIDORES DE LA HELICASA TIPO RecQ DEL SÍNDROME DE WERNER (WRN)
WO2025137640A1 (fr) * 2023-12-22 2025-06-26 Gilead Sciences, Inc. Inhibiteurs azaspiro de wrn

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0425541A1 (fr) * 1988-07-21 1991-05-08 The Upjohn Company Pyrazolo-azolo-pyrimidine-diones
WO1997011946A1 (fr) * 1995-09-28 1997-04-03 Otsuka Pharmaceutical Factory, Inc. Analgesiques
PL355148A1 (en) 1999-11-05 2004-04-05 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
AU2007260851B2 (en) 2006-06-23 2013-01-17 Incyte Corporation Purinone derivatives as HM74a agonists
US20090099195A1 (en) * 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
WO2012112363A1 (fr) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Inhibiteurs de cystéine protéases, les cathepsines
BR112014003296A2 (pt) * 2011-08-12 2017-03-14 Hoffmann La Roche composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença ou distúrbio, conjunto para o tratamento de uma condição mediada pela quinase pim e utilização do composto
WO2013182519A1 (fr) * 2012-06-04 2013-12-12 Universitaet Basel Combinaison d'agents lysosomotropiques ou de modulation de l'autophagie et d'un inhibiteur de gsk-3 pour le traitement du cancer
WO2013185124A1 (fr) 2012-06-08 2013-12-12 Wisconsin Alumni Research Foundation Composés antimicrobiens, compositions et leurs procédés d'utilisation
US9346812B2 (en) * 2013-01-16 2016-05-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
CR20200174A (es) 2020-06-26
PH12020550494A1 (en) 2021-01-11
SG11202003662XA (en) 2020-05-28
ECSP20023626A (es) 2020-06-30
US20210317128A1 (en) 2021-10-14
CN111527090A (zh) 2020-08-11
JP2021500380A (ja) 2021-01-07
KR20200078567A (ko) 2020-07-01
EP3700907B1 (fr) 2022-03-09
MX2020004981A (es) 2020-08-24
EP3700907A1 (fr) 2020-09-02
CU20200038A7 (es) 2021-03-11
DOP2020000100A (es) 2020-09-15
US11319324B2 (en) 2022-05-03
BR112020008122A2 (pt) 2020-11-03
NI202000031A (es) 2020-08-28
PE20200932A1 (es) 2020-09-17
JOP20200100A1 (ar) 2020-05-06
CO2020005065A2 (es) 2020-05-29
WO2019081343A1 (fr) 2019-05-02
AU2018354777A1 (en) 2020-04-16
CA3080249A1 (fr) 2019-05-02
DK3700907T3 (da) 2022-05-30
CL2020001107A1 (es) 2020-10-23
BR112020008122B1 (pt) 2022-11-01
ES2914377T3 (es) 2022-06-10
JP7250011B2 (ja) 2023-03-31
EA202091003A1 (ru) 2020-09-11
IL274036A (en) 2020-06-30
CN111527090B (zh) 2023-05-26

Similar Documents

Publication Publication Date Title
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
EP3873468A4 (fr) 2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
EP3601239A4 (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA45189A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA49566A (fr) Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
MA50439A (fr) Nouveaux dérivés de pyrazolo-pyrrolo-pyrimidine-dione utilisés en tant qu'inhibiteurs de p2x3
EP3733671A4 (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA51431A (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA48803A (fr) Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA47086A (fr) Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase
MA44498A (fr) Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA48987A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue